<DOC>
	<DOCNO>NCT00439569</DOCNO>
	<brief_summary>The purpose study identify maximum tolerated dosage sodium phenylbutyrate child spinal muscular atrophy type II III ; determine drug effect SMN mRNA protein level .</brief_summary>
	<brief_title>Clinical Trial Sodium Phenylbutyrate Children With Spinal Muscular Atrophy Types II III</brief_title>
	<detailed_description>Spinal muscular atrophy ( SMA ) genetic , neuromuscular disorder cause progressive degeneration motor neuron spinal cord , result loss survival motor neuron ( SMN ) protein . The disorder characterize weakness waste voluntary muscle lead cause hereditary infant death . Sodium phenylbutyrate -- drug use treat urea cycle disorder -- may increase amount SMN protein body consequently may decrease severity SMA . However , yet prove . In multicenter trial , physician evaluate multiple dosage level sodium phenylbutyrate determine maximum tolerate dose ( MTD ) , high dose safely give child SMA type II III . The initial dosage test 500 mg/kg/day . Depending upon tolerability , subsequent group may receive dosage 675 , 900 , 1200 mg/kg/day . Blood level SMN mRNA protein also measure determine whether sodium phenylbutyrate increase amount two biomarkers blood . Up 24 child enrol study sodium phenylbutyrate 12 week . The MTD determine base safety data Day 0 Day 29 visit . Participants continue monitor safety SMN mRNA protein level 12 week study drug administration period . Potential participant screen complete medical treatment history record , well undergo physical examination , laboratory test , electrocardiogram ( EKG ) . Parents eligible participant receive supply sodium phenylbutyrate instruction administer drug . Participants return clinic day 8 , 22 , 29 , week 8 12 study update medical treatment history , physical exam , blood urine collect laboratory testing . A follow-up clinic visit occur approximately 14 day last dose sodium phenylbutyrate give . During visit participant update complete medical treatment history physical examination . Duration study 14 week . Information study , part NINDS Pilot Therapeutics Network ( NPTUNE ) , may use future study determine sodium phenylbutyrate effective treating SMA , drug effect SMA symptom .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Spinal Muscular Atrophies Childhood</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<criteria>Subjects must meet follow inclusion criterion within 14 day prior receive first dose study drug . Weakness hypotonia consistent clinical diagnosis spinal muscular atrophy ( SMA ) type II III Laboratory documentation homozygous absence SMN1 exon 7 Type III subject unable get floor unaided . `` Unaided '' define use device obtain assistance another person . 2 year age old , young 12 year age , time enrollment Written inform consent parents/guardian Weight great equal 10 kilogram Laboratory result draw within 14 day prior start study drug demonstrating : Hemoglobin within normal range clinical site ; White Blood Cell Count ≥ 3000/mm³ ; Platelet Count ≥ 75,000/mm³ ; Lipase Amylase ≤ 1.5 x upper limit normal ( ULN ) absence associate clinical symptom ; AST ALT ≤ 2.5 x ULN ; Bilirubin ≤ 1.5x ULN absence associate clinical symptom ; Sodium ≥ 130 ≤ 150 mmol/L ; Potassium ≥3.0 ≤ 5.5 mmol/L ; Chloride ≤ 110 mmol/L ; Calcium ≥ 8.0 mg/dL ; Bicarbonate ≥ 16 mmol/L ; Glucose ≥ 55 ≤ 160 mg/dL ; BUN ≤ 39 mg/dL ; Creatinine ≤ 1.5 x ULN Subject expect survive least 6 month follow study entry . Subjects meet follow criterion exclude participate study : Evidence renal dysfunction , blood dyscrasia , hepatic insufficiency , symptomatic pancreatitis , cardiac arrhythmia , congenital heart defect , know history metabolic acidosis , hypertension , significant central nervous system impairment , neurodegenerative neuromuscular disease SMA . Any adverse event ≥ Grade 3 time screen base protocol toxicity grade table Any acute comorbid condition interfere wellbeing subject within 7 day enrollment include bacterial infection , viral infectious process , food poisoning , temperature &gt; 99.0ºF , need acute treatment observation due reason , judge investigator ≥ Grade 2 vomiting ; ≥ Grade 2 liver dysfunction/failure ( clinical ) ; Any abnormality note EKG except asymptomatic sinus arrhythmia History allergy/sensitivity sodium phenylbutyrate Use sodium phenylbutyrate within 30 day study entry Serious illness require systemic treatment and/or hospitalization within 14 day prior study entry ( Subjects eligible follow serious illness therapy complete subject stable , subject therapy stable least 14 day . ) Use medication intend treatment SMA include riluzole , valproic acid , hydroxyurea , oral use albuterol , sodium phenylbutyrate , butyrate derivative , creatine , carnitine , growth hormone , anabolic steroid , probenecid , oral parenteral use corticosteroid entry , haloperidol , agent anticipated increase decrease muscle strength agent know presumed histone deacetylase ( HDAC ) inhibition within 30 day prior study entry Notes : Subjects use nebulizer require inhaler receive albuterol allow study ; however oral use albuterol prohibit . Topical use steroid allow . Oral use steroid allow entry , may use clinically indicated study . Event grade base toxicitygrading table protocol .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>spinal muscular atrophy type II/III</keyword>
	<keyword>SMA type II/III</keyword>
	<keyword>spinal muscular atrophy</keyword>
	<keyword>SMA</keyword>
	<keyword>sodium phenylbutyrate</keyword>
	<keyword>motor neuron disease</keyword>
	<keyword>neuromuscular</keyword>
	<keyword>survival motor neuron</keyword>
	<keyword>SMN</keyword>
	<keyword>dose escalation</keyword>
</DOC>